Dactinomycin in acute myeloid leukemia with NPM1 mutations-Reference-Cited by-同舟云学术

Dactinomycin in acute myeloid leukemia with NPM1 mutations

Published:2020-05-25 Issue:3 Volume:105 Page:302-307
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Beziat Guillaume¹^ORCID,Tavitian Suzanne¹,Bertoli Sarah¹²,Huguet Françoise¹,Largeaud Laetitia²³,Luquet Isabelle³,Vergez François³,Rieu Jean‐Baptiste³^ORCID,Bories Pierre⁴,Delabesse Eric²³,Récher Christian¹²^ORCID

Affiliation:

1. Service d'Hématologie Institut Universitaire du Cancer de Toulouse Oncopole Centre Hospitalier Universitaire de Toulouse Toulouse France

2. Université Toulouse III Paul Sabatier Toulouse France

3. Laboratoire d’Hématologie Institut Universitaire du Cancer de Toulouse Oncopole Centre Hospitalier Universitaire de Toulouse Toulouse France

4. Réseau Onco‐Occitanie Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13438

Reference9 articles.

1. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

4. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

5. Mutant NPM1 Maintains the Leukemic State through HOX Expression

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NPM1 mutated acute myeloblastic leukaemia;HEMATOLOGIE;2023

2. Role of Natural Products in Developing Novel Anticancer Agents: A Perspective;Chemistry & Biodiversity;2022-11

3. Targeted therapy in NPM1-mutated AML: Knowns and unknowns;Frontiers in Oncology;2022-09-27

4. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia;Hematology;2022-05-27

5. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML;International Journal of Molecular Sciences;2022-03-22